Umar Mahmood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9590563/publications.pdf

Version: 2024-02-01

94 papers 8,324 citations

32 h-index 89 g-index

96 all docs

96 docs citations

96 times ranked 14105 citing authors

#	Article	IF	CITATIONS
1	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	7.7	1,892
2	In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology, 1999, 17, 375-378.	9.4	1,578
3	Arthritis Critically Dependent on Innate Immune System Players. Immunity, 2002, 16, 157-168.	6.6	631
4	Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5947-5952.	3.3	537
5	Feasibility of in Vivo Multichannel Optical Imaging of Gene Expression: Experimental Study in Mice. Radiology, 2002, 224, 446-451.	3.6	328
6	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Research, 2017, 77, 2318-2327.	0.4	235
7	Preparation of a Cathepsin D Sensitive Near-Infrared Fluorescence Probe for Imaging. Bioconjugate Chemistry, 1999, 10, 892-896.	1.8	212
8	Near-infrared optical imaging of proteases in cancer. Molecular Cancer Therapeutics, 2003, 2, 489-96.	1.9	207
9	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 631-640.	3.3	198
10	Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nature Immunology, 2006, 7, 284-292.	7.0	171
11	A novel direct activator of <scp>AMPK</scp> inhibits prostate cancer growth by blocking lipogenesis. EMBO Molecular Medicine, 2014, 6, 519-538.	3.3	168
12	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.2	113
13	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. Journal of Nuclear Medicine, 2016, 57, 1607-1611.	2.8	105
14	Radiotheranostics in Cancer Diagnosis and Management. Radiology, 2018, 286, 388-400.	3.6	91
15	Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors. Stem Cells, 2013, 31, 1706-1714.	1.4	89
16	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205.	3.2	85
17	Inflammatory arthritis can be reined in by CpG-induced DC–NK cell cross talk. Journal of Experimental Medicine, 2007, 204, 1911-1922.	4.2	84
18	Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. Gynecologic Oncology, 2009, 112, 616-622.	0.6	74

#	Article	IF	CITATIONS
19	Miniaturized Multichannel Near Infrared Endoscope for Mouse Imaging. Molecular Imaging, 2003, 2, 350-357.	0.7	71
20	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	3.2	66
21	Catheter-based in Vivo Imaging of Enzyme Activity and Gene Expression: Feasibility Study in Mice. Radiology, 2004, 231, 659-666.	3.6	62
22	Near infrared thoracoscopy of tumoral protease activity for improved detection of peripheral lung cancer. International Journal of Cancer, 2006, 118 , $2672-2677$.	2.3	57
23	PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. British Journal of Cancer, 2017, 116, 893-902.	2.9	52
24	Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdominal Radiology, 2017, 42, 1141-1151.	1.0	52
25	Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. International Journal of Oncology, 2017, 51, 281-288.	1.4	52
26	In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis, 2010, 212, 181-187.	0.4	51
27	Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 272-81.	1.0	49
28	Quantitative Real-time Catheter-based Fluorescence Molecular Imaging in Mice. Radiology, 2007, 245, 523-531.	3.6	43
29	Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy. Theranostics, 2012, 2, 227-234.	4.6	43
30	Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11419-11424.	3.3	40
31	Improving staging of rectal cancer in the pelvis: the role of PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1235-1245.	3.3	40
32	Neuroepigenetic signatures of age and sex in the living human brain. Nature Communications, 2019, 10, 2945.	5.8	36
33	Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader. Clinical Cancer Research, 2015, 21, 1340-1347.	3.2	32
34	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1871-1884.	3.3	32
35	Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. , 2020, 8, e000291.		32
36	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. Journal of Oncology Practice, 2018, 14, e722-e728.	2.5	31

#	Article	lF	Citations
37	An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis. Theranostics, 2014, 4, 893-903.	4.6	29
38	Optical Imaging of Periostin Enables Early Endoscopic Detection and Characterization of Esophageal Cancer in Mice. Gastroenterology, 2013, 144, 294-297.	0.6	28
39	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	2.8	28
40	Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2147-2154.	3.3	28
41	Clinical impact of PET/MR in treated colorectal cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2260-2269.	3.3	28
42	PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1976-1986.	3.3	25
43	Metforminâ€"an Adjunct Antineoplastic Therapyâ€"Divergently Modulates Tumor Metabolism and Proliferation, Interfering with Early Response Prediction by ¹⁸ F-FDG PET Imaging. Journal of Nuclear Medicine, 2013, 54, 252-258.	2.8	23
44	Prospective Trial with Optical Molecular Imaging for Percutaneous Interventions in Focal Hepatic Lesions. Radiology, 2015, 274, 917-926.	3.6	23
45	RSNA International Trends: A Global Perspective on the COVID-19 Pandemic and Radiology in Late 2020. Radiology, 2021, 299, E193-E203.	3.6	23
46	Interventional Optical Molecular Imaging Guidance during Percutaneous Biopsy. Radiology, 2014, 271, 770-777.	3.6	22
47	Methotrexate-Induced Accumulation of Fluorescent Annexin V in Collagen-Induced Arthritis. Molecular Imaging, 2005, 4, 153535002005041.	0.7	22
48	An overview of PET/MR, focused on clinical applications. Abdominal Radiology, 2017, 42, 631-644.	1.0	21
49	Free Somatostatin Receptor Fraction Predicts the Antiproliferative Effect of Octreotide in a Neuroendocrine Tumor Model: Implications for Dose Optimization. Cancer Research, 2013, 73, 6865-6873.	0.4	19
50	Molecular Imaging in Gastrointestinal Disease. Gastroenterology, 2007, 132, 11-14.	0.6	18
51	C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1024-1028.	0.4	18
52	Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide. Molecular Imaging and Biology, 2018, 20, 300-308.	1.3	18
53	Real-Time Multichannel Imaging Framework for Endoscopy, Catheters, and Fixed Geometry Intraoperative Systems. Molecular Imaging, 2007, 6, 7290.2007.00012.	0.7	17
54	Quantitative Endovascular Fluorescence-based Molecular Imaging through Blood of Arterial Wall Inflammation. Radiology, 2009, 251, 813-821.	3.6	17

#	Article	IF	CITATIONS
55	Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer. Journal of Nuclear Medicine, 2015, 56, 1246-1251.	2.8	17
56	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2016, 15, 234-242.	0.8	17
57	Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics, 2016, 6, 2028-2038.	4.6	15
58	Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases. Investigative Radiology, 2021, 56, 621-628.	3.5	15
59	Real-time multichannel imaging framework for endoscopy, catheters, and fixed geometry intraoperative systems. Molecular Imaging, 2007, 6, 147-55.	0.7	14
60	Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research, 2021, 27, 5353-5364.	3.2	13
61	Fluorescent Nanoparticle Imaging Allows Noninvasive Evaluation of Immune Cell Modulation in Esophageal Dysplasia. Molecular Imaging, 2014, 13, 7290.2014.00003.	0.7	12
62	Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 62-69.	1.0	12
63	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. Cancer Research, 2014, 74, 4111-4121.	0.4	11
64	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics, 2018, 8, 3380-3391.	4.6	11
65	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist, 2020, 25, 652-660.	1.9	11
66	Abrogation of antibodyâ€induced arthritis in mice by a selfâ€activating viridin prodrug and association with impaired neutrophil and endothelial cell function. Arthritis and Rheumatism, 2009, 60, 2314-2324.	6.7	10
67	PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 379-89.	1.0	10
68	Can MR Imaging Be Used to Track Delivery of Intravascularly Administered Stem Cells?. Radiology, 2004, 233, 625-626.	3.6	9
69	Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles. Journal of Nuclear Medicine, 2016, 57, 105S-110S.	2.8	8
70	Molecular MR Imaging Probes. Proceedings of the IEEE, 2005, 93, 800-808.	16.4	7
71	Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging. Radiologic Clinics of North America, 2018, 56, 821-834.	0.9	7
72	Miniaturized Multichannel Near Infrared Endoscope for Mouse Imaging. Molecular Imaging, 2003, 2, 153535002003031.	0.7	6

#	Article	IF	Citations
73	Pan and Sentinel Lymph Node Visualization Using a Near-Infrared Fluorescent Probe. Molecular Imaging, 2003, 2, 153535002003021.	0.7	6
74	The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points. Urology, 2018, 119, 23-31.	0.5	6
75	HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance. Frontiers in Oncology, 2020, 10, 554704.	1.3	6
76	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	3.3	6
77	Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 176-84.	1.0	6
78	Science to Practice: Can an Enzyme-sensitive MR Contrast Agent Be Used to Image Inflammation in Aneurysms?. Radiology, 2009, 252, 627-628.	3.6	5
79	A container closure system that allows for greater recovery of radiolabeled peptide compared to the standard borosilicate glass system. Applied Radiation and Isotopes, 2013, 80, 99-102.	0.7	5
80	Specific ¹⁸ F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone–Binding Globulin. Journal of Nuclear Medicine, 2018, 59, 1538-1543.	2.8	5
81	Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 230-242.	1.0	5
82	Pilot Clinical Trial of Indocyanine Green Fluorescence-Augmented Colonoscopy in High Risk Patients. Gastroenterology Research and Practice, 2016, 2016, 1-7.	0.7	4
83	Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology, 2022, , 1.	1.3	4
84	Coded Aperture Nuclear Scintigraphy: A Novel Small Animal Imaging Technique. Molecular Imaging, 2002, 1, 153535002002213.	0.7	3
85	Current and Future Imaging Paradigms in Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2007, 18, 132-138.	0.2	2
86	Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2021, 44, 1439-1447.	0.9	2
87	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. Molecular Imaging and Biology, 2021, 23, 930-940.	1.3	2
88	A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of Ga-DOTATOC in healthy volunteers. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 53-62.	1.0	2
89	Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics, 2022, 14, 1460.	2.0	2
90	Can a Clinically Used Chemoembolization Vehicle Improve Transgene Delivery?. Radiology, 2006, 240, 619-620.	3.6	1

#	Article	IF	CITATIONS
91	Science to Practice: Can a Targeted Nanoparticle Be Used to Image Autoimmune Nephritis?. Radiology, 2010, 255, 309-310.	3.6	1
92	Fluorescence multi-scale endoscopy and its applications in the study and diagnosis of gastro-intestinal diseases: set-up design and software implementation. Proceedings of SPIE, 2015, , .	0.8	0
93	Abstract 1309: HSV1 oncolytic therapy for breast cancer meningeal metastases. , 2021, , .		O
94	A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases Journal of Clinical Oncology, 2020, 38, 1062-1062.	0.8	0